• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Plasminogen activator inhibitor-1: a novel therapeutic target for hypertension?

作者信息

Simon Daniel I, Simon Norman M

机构信息

Department of Medicine, Harrington Heart and Vascular Institute, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH (D.I.S.); and Division of Nephrology and Hypertension, North Shore University Health System, Evanston, IL (N.M.S.).

出版信息

Circulation. 2013 Nov 19;128(21):2286-8. doi: 10.1161/CIRCULATIONAHA.113.006321. Epub 2013 Oct 3.

DOI:10.1161/CIRCULATIONAHA.113.006321
PMID:24092816
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3997105/
Abstract
摘要

相似文献

1
Plasminogen activator inhibitor-1: a novel therapeutic target for hypertension?纤溶酶原激活物抑制剂-1：高血压的新型治疗靶点？
Circulation. 2013 Nov 19;128(21):2286-8. doi: 10.1161/CIRCULATIONAHA.113.006321. Epub 2013 Oct 3.
2
Letter by Tsuda regarding article, "Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence".津田就文章《纤溶酶原激活物抑制剂-1拮抗剂TM5441减轻Nω-硝基-L-精氨酸甲酯诱导的高血压和血管衰老》所写的信
Circulation. 2014 Aug 26;130(9):e83. doi: 10.1161/CIRCULATIONAHA.113.007940.
3
Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence.纤溶酶原激活物抑制剂-1 拮抗剂 TM5441 可减轻 Nω-硝基-L-精氨酸甲酯诱导的高血压和血管衰老。
Circulation. 2013 Nov 19;128(21):2318-24. doi: 10.1161/CIRCULATIONAHA.113.003192. Epub 2013 Oct 3.
4
A novel plasminogen activator inhibitor-1 inhibitor, TM5441, protects against high-fat diet-induced obesity and adipocyte injury in mice.一种新型纤溶酶原激活物抑制剂-1抑制剂TM5441可保护小鼠免受高脂饮食诱导的肥胖和脂肪细胞损伤。
Br J Pharmacol. 2016 Sep;173(17):2622-32. doi: 10.1111/bph.13541. Epub 2016 Jul 28.
5
Hemostasis imbalance in experimental hypertension.实验性高血压中的止血平衡失调
Mol Med. 2002 Apr;8(4):169-78.
6
Endogenous NO regulates plasminogen activator inhibitor-1 during angiotensin-converting enzyme inhibition.内源性一氧化氮在血管紧张素转换酶抑制过程中调节纤溶酶原激活物抑制剂-1。
Hypertension. 2006 Mar;47(3):441-8. doi: 10.1161/01.HYP.0000202478.79587.1a. Epub 2006 Jan 23.
7
Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition.纤溶酶原激活物抑制剂-1缺乏可预防因长期抑制一氧化氮合酶而导致的高血压和血管纤维化。
Circulation. 2001 Aug 14;104(7):839-44. doi: 10.1161/hc3301.092803.
8
Plasminogen activator inhibitor-1 regulates macrophage-dependent postoperative adhesion by enhancing EGF-HER1 signaling in mice.纤溶酶原激活物抑制剂-1通过增强小鼠体内的表皮生长因子-人表皮生长因子受体1信号传导来调节巨噬细胞依赖性术后粘连。
FASEB J. 2017 Jun;31(6):2625-2637. doi: 10.1096/fj.201600871RR. Epub 2017 Mar 7.
9
The serpin protease-nexin 1 is present in rat aortic smooth muscle cells and is upregulated in L-NAME hypertensive rats.丝氨酸蛋白酶抑制因子蛋白酶连接蛋白1存在于大鼠主动脉平滑肌细胞中，且在L-硝基精氨酸甲酯诱导的高血压大鼠中上调。
Arterioscler Thromb Vasc Biol. 2003 Jan 1;23(1):142-7. doi: 10.1161/01.atv.0000047867.98019.2d.
10
Three monoclonal antibodies against the serpin protease nexin-1 prevent protease translocation.三种针对丝氨酸蛋白酶神经氨酸-1 的单克隆抗体可阻止蛋白酶易位。
Thromb Haemost. 2014 Jan;111(1):29-40. doi: 10.1160/TH13-04-0340. Epub 2013 Oct 2.

引用本文的文献

1
Lead Acetate Exposure and Cerebral Amyloid Accumulation: Mechanistic Evaluations in APP/PS1 Mice.醋酸铅暴露与脑淀粉样蛋白沉积：APP/PS1 小鼠的机制评估。
Environ Health Perspect. 2024 Oct;132(10):107004. doi: 10.1289/EHP14384. Epub 2024 Oct 16.
2
Low Cortisone as a Novel Predictor of the Low-Renin Phenotype.低皮质醇作为低肾素表型的新型预测指标
J Endocr Soc. 2024 Mar 15;8(6):bvae051. doi: 10.1210/jendso/bvae051. eCollection 2024 Apr 6.
3
Pharmacological inhibition of plasminogen activator inhibitor-1 prevents memory deficits and reduces neuropathology in APP/PS1 mice.纤溶酶原激活物抑制剂-1 的药理学抑制可预防 APP/PS1 小鼠的记忆缺陷和减少神经病理学改变。
Psychopharmacology (Berl). 2023 Dec;240(12):2641-2655. doi: 10.1007/s00213-023-06459-8. Epub 2023 Sep 12.
4
Oncostatin M, Serpins, and Oxidative Stress in Extracellular Matrix Remodeling and Arteriovenous Fistula Maturation.抑瘤素M、丝氨酸蛋白酶抑制剂与细胞外基质重塑及动静脉内瘘成熟中的氧化应激
Cardiol Cardiovasc Med. 2023;7(2):129-140. doi: 10.26502/fccm.92920318. Epub 2023 Apr 20.
5
PAI-1 Inhibition - Another Therapeutic Option for Cardiovascular Protection.纤溶酶原激活物抑制剂-1抑制作用——心血管保护的另一种治疗选择
Maedica (Bucur). 2015 Jun;10(2):147-152.
6
Urinary alpha-1 antitrypsin and CD59 glycoprotein predict albuminuria development in hypertensive patients under chronic renin-angiotensin system suppression.尿α-1抗胰蛋白酶和CD59糖蛋白可预测慢性肾素-血管紧张素系统抑制状态下高血压患者蛋白尿的发生。
Cardiovasc Diabetol. 2016 Jan 16;15:8. doi: 10.1186/s12933-016-0331-7.
7
Ets-1 upregulation mediates angiotensin II-related cardiac fibrosis.Ets-1上调介导血管紧张素II相关的心脏纤维化。
Int J Clin Exp Pathol. 2015 Sep 1;8(9):10216-27. eCollection 2015.
8
Chemical Antagonists of Plasminogen Activator Inhibitor-1: Mechanisms of Action and Therapeutic Potential in Vascular Disease.纤溶酶原激活物抑制剂-1的化学拮抗剂：作用机制及在血管疾病中的治疗潜力
J Mol Genet Med. 2014 Oct;8(3). doi: 10.4172/1747-0862.1000125.

本文引用的文献

1
Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence.纤溶酶原激活物抑制剂-1 拮抗剂 TM5441 可减轻 Nω-硝基-L-精氨酸甲酯诱导的高血压和血管衰老。
Circulation. 2013 Nov 19;128(21):2318-24. doi: 10.1161/CIRCULATIONAHA.113.003192. Epub 2013 Oct 3.
2
Multimarker approach to evaluate correlates of vascular stiffness: the Framingham Heart Study.评估血管僵硬度相关因素的多标志物方法：弗雷明汉心脏研究
Circulation. 2009 Jan 6;119(1):37-43. doi: 10.1161/CIRCULATIONAHA.108.816108. Epub 2008 Dec 22.
3
Reactive site-dependent phenotypic alterations in plasminogen activator inhibitor-1 transgenic mice.纤溶酶原激活物抑制剂-1转基因小鼠中反应位点依赖性的表型改变
J Thromb Haemost. 2007 Jul;5(7):1500-8. doi: 10.1111/j.1538-7836.2007.02587.x. Epub 2007 Apr 16.
4
Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review.肾素-血管紧张素-醛固酮系统在血管重塑和炎症中的作用：一项临床综述
J Hypertens. 2006 Jun;24(6):983-91. doi: 10.1097/01.hjh.0000226182.60321.69.
5
Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling.纤溶酶原激活物抑制剂-1的药理学抑制和基因缺陷可减轻血管紧张素II/盐诱导的主动脉重塑。
Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):365-71. doi: 10.1161/01.ATV.0000152356.85791.52. Epub 2004 Dec 2.
6
Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases.高血压与心血管疾病中动脉僵硬度和脉压的当前观点
Circulation. 2003 Jun 10;107(22):2864-9. doi: 10.1161/01.CIR.0000069826.36125.B4.
7
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.美国国家高血压预防、检测、评估与治疗联合委员会第七次报告：JNC 7报告。
JAMA. 2003 May 21;289(19):2560-72. doi: 10.1001/jama.289.19.2560. Epub 2003 May 14.
8
Pulse pressure, arterial stiffness, and drug treatment of hypertension.脉压、动脉僵硬度与高血压的药物治疗
Hypertension. 2001 Oct;38(4):914-21. doi: 10.1161/hy1001.095773.
9
Nonfibrinolytic functions of plasminogen.纤溶酶原的非纤维蛋白溶解功能。
Methods. 2000 Jun;21(2):103-10. doi: 10.1006/meth.2000.0981.
10
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure.抑制纤溶酶原激活剂或基质金属蛋白酶可预防心脏破裂，但会损害治疗性血管生成并导致心力衰竭。
Nat Med. 1999 Oct;5(10):1135-42. doi: 10.1038/13459.